Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALA-5 trial of 5-ALA plus carmustine wafers in primary glioblastoma surgery
2010-022496-66Phase 2Completed
- Sponsor
- UCLH
- Start
- Jan 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid and carmustine in glioblastoma (GBM), sponsored by UCLH. Primary endpoints: Procedure compliance, Post-operative complication rate and 4 more. Started Jan 2011; status: completed.
02
Drugs
5-aminolevulinic acidcarmustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2010-022496-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022496-66.